The global cannabidiol (CBD) market sits at $24.61 billion in 2026 per Fortune Business Insights, but that single figure obscures a measurement debate that spans $10.68 billion to $30.21 billion depending on whether a firm counts finished CBD oils only or every product that contains CBD as an ingredient. This article presents the 2026 cannabidiol market statistics in full — market size by research firm, US state-level data, product segment splits, regulatory milestones from 2024 and 2025, and the corporate developments reshaping the competitive landscape.
Cannabidiol Market Statistics in 2026 — TL;DR
Fortune Business Insights values the global CBD market at $24.61 billion in 2026 and $382.04 billion by 2034, implying a 40.89% CAGR — the highest forecast of any major research firm.
Grand View Research and Polaris Market Research use narrower product definitions, producing 2024–2025 base values of $10.68 billion and $9.81 billion respectively, with CAGRs between 13.70% and 16.1%.
The US CBD market is projected at $9.78 billion in 2026 alone, with a long-run projection of $78.74 billion by 2032 from Fortune Business Insights.
Pharmaceuticals hold 36.9% of CBD application revenue in 2026. Oils and tinctures lead product form at 37.48%. Gummies are growing fastest at a 29.35% CAGR through 2031.
E-commerce is the fastest-growing distribution channel at 21.86% CAGR through 2031, outpacing retail stores which hold 46.02% of current channel share.
How Large Is the Global Cannabidiol Market in 2026?
The CBD market has a persistent measurement problem. Fortune Business Insights places 2026 at $24.61 billion. Market Research Future puts 2025 at $30.21 billion using the widest scope — every product where CBD is present, including pet food, fortified beverages, and personal care. Grand View Research, which tracks only finished CBD-primary products, records $10.68 billion for 2025. The 3x spread between these figures does not reflect disagreement about the market’s direction — all firms agree it is growing quickly — it reflects disagreement about what counts.
The pharmaceutical layer is the most consequential variable. When a firm includes pharmaceutical-grade CBD products alongside wellness oils and cosmetics, base values nearly double. Firms applying narrower scope definitions produce more conservative figures but also more defensible short-term numbers, since regulatory barriers limit pharmaceutical CBD adoption in most markets outside the US and UK.
Cannabidiol Market Size Estimates by Research Firm (2025–2026)
| Research Firm | Base Year Value | 2026 Projection | Forecast End Value | CAGR |
|---|---|---|---|---|
| Fortune Business Insights | $16.52B (2025) | $24.61B | $382.04B (2034) | 40.89% |
| Market Data Forecast | $26.25B (2025) | — | $140.2B (2033) | 23.3% |
| Market Research Future | $30.21B (2025) | — | $89.89B (2035) | 11.52% |
| Grand View Research | $10.68B (2025) | — | $30.96B (2033) | 13.70% |
| Straits Research | $13.14B (2025) | — | $51.43B (2033) | 18.6% |
| Polaris Market Research | $9.81B (2024) | — | — | 16.1% |
| Technavio | — | — | +$56.5B growth (2024–29) | 24.8% |
The widest internal consistency check in this table: Market Research Future’s $30.21 billion base (2025) combined with its 11.52% CAGR produces a 2035 terminal value of $89.89 billion. Fortune Business Insights’ $16.52 billion base (2025) combined with its 40.89% CAGR produces $382.04 billion by 2034. The Fortune terminal value is 4.25x larger despite a lower starting point — reflecting a much steeper regulatory liberalisation assumption for Asia, MEA, and parts of Europe where CBD remains restricted.
Cannabidiol Market Statistics by Product and Application Segment
Oils and tinctures led all product forms with 37.48% of revenue in 2025, per Mordor Intelligence’s January 2026 report. The gummies and confectionery category posted the fastest growth rate of any product form at a 29.35% CAGR through 2031 — reflecting both the shift toward consumer-friendly formats and the lower regulatory complexity of food-type products versus oils in several European and Asian markets.
On the application side, pharmaceuticals held 36.9% of the market in 2026 per Fortune Business Insights, and Grand View Research independently designated the pharmaceutical segment as the largest in 2025. The biopharmaceutical sector’s growing interest in cannabinoid-based therapies — particularly for neurological indications — is one structural driver behind this segment’s sustained dominance across multiple research firm scope definitions.
Retail stores captured 46.02% of distribution revenue in 2025, but e-commerce is now the fastest-growing channel at a 21.86% CAGR through 2031. Major pharmacy retail chains that began stocking hemp-derived CBD products in 2019 have become a significant physical distribution layer, while direct-to-consumer online sales continue to take share in markets where regulations allow.
| Segment | Detail | Share / CAGR | Source |
|---|---|---|---|
| Oils & tinctures | Largest product form (2025) | 37.48% | Mordor Intelligence, Jan 2026 |
| Gummies & confectionery | Fastest-growing form | 29.35% CAGR (to 2031) | Mordor Intelligence, Jan 2026 |
| Pharmaceuticals | Largest application (2026) | 36.9% | Fortune Business Insights |
| Cosmetics | Second-largest application | — | Grand View Research |
| Retail stores | Largest distribution channel (2025) | 46.02% | Mordor Intelligence, Jan 2026 |
| E-commerce | Fastest-growing channel | 21.86% CAGR (to 2031) | Mordor Intelligence, Jan 2026 |
| Marijuana-derived | Dominant source (Fortune scope) | 56.07% (2026) | Fortune Business Insights |
| Hemp-derived | Dominant in B2B/retail (GVR scope) | Largest in B2B segment | Grand View Research |
| B2B end-user | Largest by sales type (2025) | Largest share | Grand View Research |
The source-type conflict — Fortune Business Insights designating marijuana-derived CBD at 56.07% while Grand View Research designates hemp-derived as dominant — traces to the same scope split operating in the overall market size discrepancy. Fortune Business Insights counts pharmaceutical-grade CBD, where high-concentration marijuana-derived extracts are commercially dominant. Grand View Research’s B2B and retail focus weights hemp-derived CBD more heavily because its THC-below-0.3% classification is legally cleaner for multinational retailers, particularly in Europe and Japan where THC limits are strictly enforced.
Cannabidiol Market Statistics by Region (2025–2026)
North America is the largest CBD region regardless of which research firm you use, though the share reported varies significantly. Fortune Business Insights and Mordor Intelligence both place North America near 47%, while Grand View Research reports 85.80% — a figure that narrows when broader product scopes redistribute share toward Asia Pacific’s cosmetics and beverage markets. The United States alone is projected at $9.78 billion in 2026, with a long-term projection of $78.74 billion by 2032 per Fortune Business Insights.
Europe recorded $4.22 billion in 2025, with the UK projected at $1.76 billion and Germany at $1.19 billion in 2026. The UK’s regulatory trajectory is particularly active: the Food Standards Agency opened a novel food consultation on CBD products in September 2025. Major pharmacy and retail distributors operating in the UK and Europe have been positioning their CBD product ranges ahead of potential FSA approvals.
| Region | 2025 Value | 2026 Projected | Share (2025, Fortune) | Key Country Data |
|---|---|---|---|---|
| North America | $7.87B | $11.8B | 47.63% | US: $9.78B (2026) |
| Europe | $4.22B | $6.28B | 25.52% | UK: $1.76B; Germany: $1.19B |
| Asia Pacific | $2.88B | $4.28B | 17.47% | China: $1.84B; Japan: $1.1B; India: $0.46B |
| Latin America | $0.90B | $1.32B | 5.42% | — |
| Middle East & Africa | $0.65B | $0.93B | 3.96% | — |
Asia Pacific: Fastest-Growing Cannabidiol Market Region
Every major research firm — Grand View Research, Mordor Intelligence, Fortune Business Insights, and Straits Research — designates Asia Pacific as the fastest-growing CBD region. Mordor Intelligence records a 19.74% CAGR through 2031, the most specific figure available. China is projected at $1.84 billion in 2026, Japan at $1.1 billion, and India at $0.46 billion. Thailand became the first Southeast Asian country to legalise cannabis for medicinal use in 2019, opening a regional template that other Southeast Asian governments have since evaluated.
China’s contribution to APAC growth is primarily through the cosmetics and personal care sector, where CBD-infused skincare has seen rapid consumer uptake without the same pharmaceutical pathway requirements that apply in the US and UK. Japan’s $1.1 billion projection reflects a combination of advanced telecommunications infrastructure, high smartphone penetration, and an ageing population that has driven demand for wellness and chronic condition management products.
Key Cannabidiol Market Regulatory Events in 2024–2025
The most commercially significant regulatory event of 2025 was the FDA’s March 2025 approval of Epidiolex for tuberous sclerosis complex. This expanded Epidiolex’s approved indications beyond its original 2018 approval for Lennox-Gastaut syndrome and Dravet syndrome. Each new FDA-approved indication supports the pharmaceutical segment’s leadership position and gives prescribing physicians broader grounds for recommending a CBD-based treatment — a development that pharmaceutical companies across the industry, including those building cannabinoid-adjacent drug pipelines, have tracked closely.
In September 2025, the UK Food Standards Agency opened a consultation on approving the first CBD food products as novel foods, covering three applications and proposing safety warnings on products with higher CBD concentrations. On the corporate side, Canopy Growth raised $300 million through convertible debenture financing in November 2024 (Source: Canopy Growth SEC filing), and Aurora Cannabis partnered with Vectura and Fertin Pharma to launch the LUO CBD lozenge in September 2024 (Source: Grand View Research citing Aurora Cannabis). British Cannabis acquired Goodbody Botanicals in February 2024, expanding its cosmetics and herbal wellness range.
Why CBD Market CAGR Estimates Vary So Widely
The 11.52% to 40.89% CAGR range across research firms is the widest in any market covered in this research series — and the explanation is not statistical error. Market Research Future’s 11.52% CAGR applies to a $30.21 billion (2025) base, producing a 2035 terminal value of $89.89 billion. Fortune Business Insights’ 40.89% CAGR applies to a $16.52 billion (2025) base, producing a 2034 terminal value of $382.04 billion. Both projections are internally consistent. The difference is a regulatory assumption: Fortune’s model assumes that currently restricted markets — most of the Middle East, large parts of Southeast Asia, and several Latin American countries — undergo meaningful legalisation within the forecast window. Market Research Future’s model assumes a more conservative adoption pace in those same markets.
The Technavio estimate — $56.5 billion in market growth across 2024–2029 at a 24.8% CAGR — sits at the midpoint of the range and represents the most widely cited intermediate figure because it uses a five-year forecast window that minimises long-run regulatory assumptions. Retail expansion by major health and pharmacy chains into CBD-adjacent product categories is one of the concrete near-term drivers underpinning Technavio’s mid-range CAGR estimate.
FAQs
How big is the global cannabidiol market in 2026?
Fortune Business Insights projects the global CBD market at $24.61 billion in 2026. Other research firms using narrower product definitions place the 2025 base between $9.81 billion (Polaris) and $10.68 billion (Grand View Research). Market Research Future, using the broadest scope, values 2025 at $30.21 billion.
What is the CBD market CAGR for 2026–2034?
CAGRs range from 11.52% (Market Research Future, 2025–2035) to 40.89% (Fortune Business Insights, 2026–2034). Technavio’s five-year estimate of 24.8% (2024–2029) sits at the midpoint. The variance reflects different regulatory adoption assumptions for restricted markets in Asia and the Middle East.
Which region leads the cannabidiol market?
North America leads globally. Fortune Business Insights and Mordor Intelligence both place North American share near 47%, while Grand View Research’s narrower scope produces a 85.80% figure. The US alone is projected at $9.78 billion in 2026 and $78.74 billion by 2032 per Fortune Business Insights.
What is the fastest-growing CBD product form?
Gummies and confectionery recorded the fastest product form growth at a 29.35% CAGR through 2031 per Mordor Intelligence’s January 2026 report, outpacing the overall market CAGR on most estimates.
What was the most significant CBD regulatory event in 2025?
The FDA’s March 2025 approval of Epidiolex for tuberous sclerosis complex expanded the drug’s approved indications beyond epilepsy for the first time since its 2018 launch, directly strengthening the pharmaceutical segment’s share of application revenue.
Sources:
https://www.fortunebusinessinsights.com/cannabidiol-cbd-market-103215
https://www.marketresearchfuture.com/reports/cbd-market-8090
https://www.polarismarketresearch.com/industry-analysis/cannabidiol-market
